

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on March 2, 2007

**PATENT**  
Attorney Docket No.: 021911-000500US  
Client Reference No.: OBM30

TOWNSEND and TOWNSEND and CREW LLP

By: *Timothy J. Paulin*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent No. 7,148,035 B1

Miles William Carroll, et al.

Application No.: 09/533,798

Filed: March 24, 2000

For: POLYPEPTIDE

Customer No. 20350

Examiner: Salimi, Ali Reza

Art Unit: 1648

CITATION OF PRIOR ART  
UNDER 37 CFR §1.501(a)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned attorney respectfully requests that the references cited on attached Form PTO/SB/42 and submitted herewith be placed in the Patent Office file for the above-referenced patent under the provisions of 37 CFR §1.501(a).

The submitted references and remarks have been provided to update the Patent Office file wrapper for the above-referenced patent.

It is not believed that there are any required fees associated with this submission. Should any fees be required, however, those fees may be charged to the undersigned's Deposit Account No. 20-1430.

Respectfully submitted,

*Karen Babyak Dow*  
Karen B. Dow  
Reg. No. 29,684

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 858-350-6100; Fax: 415-576-0300  
KBD/tsp

60994856 v1

<b>37 CFR 1.501</b> <b>INFORMATION DISCLOSURE CITATION</b> <b>IN A PATENT</b> (Sheet <u>1</u> of <u>2</u> )				Docket Number (Optional)		Patent Number	
				021911-000500US		7,148,035 B1	
				Applicant Miles William Carroll, et al.			
Issue Date 12/12/2006				Art Unit 1648			
<b>U. S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AA							
AB							
AC							
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
AD	WO/97/19183	5/29/1997	PCT				
AE							
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
AF	CORREALE, P., et al. "Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligopeptide peptide", <i>J. Immunol.</i> (1998) 161(6):3186-94						
AG	HODGE, J.W., et al. "A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate", <i>Int. J. Cancer</i> (1995) 63(2):231-7						
AH	HOLE & Stern, "A 72 kD trophoblast glycoprotein defined by a monoclonal antibody", <i>Br. J. Cancer</i> (1988) 57:239-246						
AI	IRVINE, et al. "Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL", <i>J. Immunol.</i> (1995) 154(9):4651-7						
AJ	JACKSON, R.J., et al. "Infertility in Mice Induced by a Recombinant Ectromelia Virus Expressing Mouse Zonae Pellucida Glycoprotein 3", <i>Biol. Reprod.</i> (1998) 58(1):152-159						
AK	KASS, et al. "Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus", <i>Cancer Research</i> (1999) 59:678-683						
AL	ROSATO, et al. "CTL Response and Protection Against P815 Tumor Challenge in Mice Immunized with DNA Expressing the Tumor-Specific-Antigen P815A", <i>Human Gene Therapy</i> (1997) 8:1451-1458						
AM	SANDA, M.G., et al. "Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer", <i>Urology</i> (1999) 53(2):260-6						
AN	SOUTHALL, et al. "Immunohistological distribution of 5T4 antigen in normal malignant tissues", <i>Br. J. Cancer</i> (1990) 61:89-95						
AO	TSANG, et al. "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen: Epitopes From Patent Immunized with Recombinant Vaccinia-CEA Vaccine", <i>J. Natl. Cancer Inst.</i> (1995) 87(13):982-990						
AP	WANG, Rong-Fu "Tumor Antigen Discovery: Perspectives for Cancer Therapy", <i>Molecular Medicine</i> (1997) 3(11):716-731						

**37 CFR 1.501**  
**INFORMATION DISCLOSURE CITATION**  
**IN A PATENT**

(Sheet 2 of 2)

Docket Number (Optional)  
021911-000500US

Patent Number  
7,148,035 B1

Applicant Miles William Carroll, et al.

Issue Date 12/12/2006

Art Unit 1648

AQ	COULIE P. "Human Tumor Antigens Recognized by Cytolytic T Lymphocytes", Chapter 5, pages 95-125, <i>Tumor Immunology</i> , Eds. Daglish & Browning, Cambridge University Press 1996
AR	ROSENKRANTZ, K., et al. "Generation and regulation of autotoxicity in mixed lymphocyte cultures: Evidence for active suppression of autotoxic cells", <i>PNAS</i> (1985) 82:4506-4512
AS	STAVELY-O'CARROLL, et al. "Induction of antigen-specific T cell energy: An early event in the course of tumor progression", <i>PNAS</i> (1998) 95:1178-1183
AT	MANSON, L., et al. "Short Analytical Review - Anti-tumor Immune Responses of the Tumor Bearing Host. The Case for Antibody-Mediated Immunologic Enhancement", <i>Clinical Immunology &amp; Immunopathology</i> (1994) 72(1):1-8
AU	GANSS, R., et al. "Tumor Microenvironment Can Restrict the Effectiveness of Activated Antitumor Lymphocytes", <i>Cancer Research</i> (1998) 58:4673-4681
AV	BERD, D. "Cancer Vaccines. Reborn or Just Recycled?", <i>Seminars in Oncology</i> (1998) 25(6):605-610
AW	HERSEY P., et al. "Impediments to Successful Immunotherapy", <i>Pharmacol. Ther.</i> (1999) 81(2):111-119
AX	TAKAHASHI, K., et al. "Escape Mechanisms of Melanoma From Immune System By Soluble Melanoma Antigen", <i>The Journal of Immunology</i> (1988) 140(9):3244-3248
AY	JANEWAY & TRAVERS, <i>Immunobiology: The Immune System in Health and Disease</i> , Third edition, Current Biology Ltd./Garland Publishing Inc. (1997)
AZ	AMATO, R., et al. "Phase II Trial to Assess the Activity of MVA 5T4 (Troxax®) alone versus MVA 5T4 plus Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in Patients (pts) with Progressive Hormone Refractory Prostate Cancer (HRPC), Abstract, 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", 7-10 November 2006, Prague, Czech Republic
BA	AMATO, R., et al. "Activity of MVA 5T4 alone or in Combination with either Interleukin-2 (IL-2), Interferon-α (IFN), or Sunitinib in Patients (Pts) with Metastatic Renal Cell Cancer (MRCC), Abstract, 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", 7-10 November 2006, Prague, Czech Republic
BB	SYKULEV, Y., et al. "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response", <i>Immunity</i> (1995) 4:565-571
EXAMINER	DATE CONSIDERED